{"entity":{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","aka":["KANNON"],"tldr":"A phase 2 trial of PLB1004 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., active and no longer recruiting.","summary":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) is a phase 2 interventional study registered as NCT06015503 by Avistone Biotechnology Co., Ltd., with 139 participants enrolled, started 2023-07-21 and due to reach its primary completion in 2025-03-06. Interventions recorded: PLB1004.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06015503","url":"https://clinicaltrials.gov/study/NCT06015503"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct06015503-j-thorac-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06015503","phase":"2","setting":"A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","sponsor":"Avistone Biotechnology Co., Ltd.","participation":[{"nct":"NCT06015503","source":"https://clinicaltrials.gov/study/NCT06015503","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"219ffe020a8fbcc271b6c7e4722ad0f72251016284ea3c4cbe9d3f398fbdccd8","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-22","leadSponsor":"Avistone Biotechnology Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":139,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2023-07-21","startedType":"actual","enrolled":139,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06015503/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}],"paper":[{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/"}]}}